Direct Comparison Not Available in Evidence
A direct suicide risk ratio comparing atomoxetine (Strattera) to varenicline (Chantix) cannot be calculated from the available evidence, as these medications are used for entirely different indications (ADHD vs. smoking cessation) and have not been studied head-to-head for suicide risk.
Individual Suicide Risk Profiles
Atomoxetine (Strattera)
Atomoxetine carries an FDA black box warning for suicidal ideation in children and adolescents with ADHD. 1
- Absolute risk in pediatric patients: 0.4% (5/1357) experienced suicidal ideation vs. 0% (0/851) in placebo 1, 2
- Risk difference: 0.46% (95% CI 0.09-0.83; p=0.016) 2
- Number needed to harm (NNH): 227 2
- No completed suicides occurred in clinical trials 1, 2
- Adult patients: No increased risk observed in similar trials 3, 4
The meta-analysis by Bangs et al. found the Mantel-Haenszel risk ratio was 2.92 (95% CI 0.63-13.57; p=0.172), though the incidence difference was statistically significant 2. A later 2014 meta-analysis including both pediatric and adult populations confirmed suicidal ideation was more frequent in pediatric patients (MHRR=1.63; p=0.41) but found no evidence of increased suicidal behavior 4.
Critical monitoring period: First few months of treatment and after dose changes 3, 1
Varenicline (Chantix)
Varenicline previously carried warnings for neuropsychiatric events including suicidal ideation, but recent evidence has largely refuted these concerns. 5, 6
- 2015 meta-analysis (39 RCTs, 10,761 participants): No evidence of increased risk of suicide attempts (OR 1.67,95% CI 0.33-8.57), suicidal ideation (OR 0.58,95% CI 0.28-1.20), or depression (OR 0.96,95% CI 0.75-1.22) compared to placebo 6
- EAGLES trial (2016): A large multicenter RCT in patients with and without psychiatric disorders found neuropsychiatric adverse event rates with varenicline were not significantly increased relative to nicotine patches or placebo 5
- Actual increased risks: Sleep disorders (OR 1.63), insomnia (OR 1.56), abnormal dreams (OR 2.38), and fatigue (OR 1.28) 6
- Reduced risk: Anxiety (OR 0.75,95% CI 0.61-0.93) 6
The 2016 NCCN guidelines note that while providers should monitor for neuropsychiatric issues, "the substantial benefits of immediate smoking cessation versus risks of increased hostility, depression, or suicidal behavior" should be weighed 5.
Clinical Context Matters
These medications cannot be directly compared for suicide risk because:
- Different patient populations: ADHD patients (atomoxetine) have inherently different baseline suicide risk than smokers seeking cessation (varenicline)
- Different age groups studied: Atomoxetine's risk is primarily in pediatric populations; varenicline is studied predominantly in adults
- Different underlying conditions: ADHD itself carries suicide risk; smoking cessation can temporarily increase psychiatric symptoms
- Different study designs and outcome measures: Pediatric ADHD trials vs. adult smoking cessation trials use different assessment methods
Practical Clinical Guidance
For Atomoxetine:
- Mandatory close monitoring in all pediatric patients, especially first month and after dose changes 3, 1
- Educate families about warning signs: agitation, irritability, unusual behavior changes, suicidal thoughts 3
- Consider alternative ADHD medications (stimulants, alpha-2 agonists) in patients with prior suicidal ideation 3
- Adult patients can be reassured of no increased risk 4
For Varenicline:
- Current evidence supports safety regarding suicide risk, even in psychiatric populations 5, 6
- Historic concerns about neuropsychiatric events have been largely refuted by rigorous trials 6
- Monitor for common side effects (sleep disturbances, nausea) rather than suicide risk 5, 6
- Can be used in patients with psychiatric comorbidities, though some providers remain hesitant due to historic warnings 7
The question itself reflects a category error—these medications serve different purposes in different populations and cannot be meaningfully compared for suicide risk ratios.